Causative Gene and its Associated Gene for Parkinson Disease and Dystonia

Brain and Nerve

Volumn 61, Issue 4, 2009, Pages 447-463

  Hasegawa, Kazuko ^a   Toyoshima, Itaru ^b  

^a SAGAMIHARA NATIONAL HOSPITAL   (Japan)

^b AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Associated gene for parkinson disease; DYT series; PARK series; Parkinsonism

Indexed keywords

CARRIER PROTEIN; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; PROTEIN TORSIN A; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHAGY; CELL DEATH; CLINICAL FEATURE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DYSTONIA; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GENE IDENTIFICATION; HEREDITY; HUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN DEGRADATION;

ALPHA-SYNUCLEIN; DYSTONIA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR CHAPERONES; ONCOGENE PROTEINS; PARKINSON DISEASE; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTON-TRANSLOCATING ATPASES; TATA-BINDING PROTEIN ASSOCIATED FACTORS; TRANSCRIPTION FACTOR TFIID; UBIQUITIN THIOLESTERASE; UBIQUITIN-PROTEIN LIGASES;

EID: 64849090236     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (120)

1. ) Caparros-Lefebvre D, Elbaz A: Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Caribben Parkinsonism Study Group. Lancet 354: 281-286, 1999
2. Tanner CM, Ottman R, Goldman SM, Elleberg J, Chan P, et al: Parkinson disease in twins: an etiologic study. Ann Neurol 45: 577-582, 1999
3. ) Sveinbjornsdottir S, Hicks AA, Jonsson T, Petirsspm J, Gugmundsson G, et al: Familial aggregation of Parkinson's disease in Iceland. N Engl J Med 343: 1765-1770, 2000
4. OMIM # 168600, + 124030, z.ast; 605558, z.ast; 606441, z.ast; 606463, + 157140, z.ast; 601828, # 556500
5. ) Momose Y, Murata M, Kobayashi K, Tachikawa M, Nakabayashi Y, et al: Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann Neurol 51: 133-136, 2002
6. Mara ganore DM, Lesnick TG, Elbaz A, Chartier- Harlin MC, Gasser T, et al: UCHL1 is a Parkinson's disease suspetibility gene. Ann Neurol 55:512-521, 2004
7. Van der Walt JM, Noureddine MA, Kittappa R, Hauser MA, Scott WK, et al: Fibroblast growth factor 20 gene and Parkinson's disease. Am J Hum Genet 74: 1121-1127, 2004
8. Mueller JC, Fuchs J, Hofer A, Zimprich A, Lichtner P, et al: Multiple regions of α-synuclerin are associated with Parkinson's disease. Ann Neurol 57: 535-541, 2005
9. Di Fonzo A, Wu-Chow YH, Lu C, Svan Doeselaar M, Simons EJ, et al: A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 7: 133- 138, 2006
10. Arawaka S, Wada M, Goto S, Karube H, Sakamoto M, et al:The role of G-protein-coupled receptor kinase5 in pathogenesis of sporadic Parkinson's disease.J Neurosci 26: 9227-9238, 2006
11. Golbe LI, Dilorio G Bonavita B Miller DC, Duviosin RC: A large kindred with autosomal dominant Parkinson's disease. Ann Neurol 27: 276-282, 1990
12. Spira PJ, Sharpe DM, Halliday G, Cavanagh J, Nicholson GA: Clinical and pathological features of a Parkinsonian syndrome in a family with an ala53-to-thr alpha-synuclein mutation. Ann Neurol 49: 313-319, 2001
13. Polymerapoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al: Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047, 1997
14. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D: Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305: 1292-1295, 2004
15. Shimura H, Scholossmacher MG, Hattori N, Frosch M, Trockenbacher A, et al: Ubiquitination of a new form of alpha-synuclein bay parkin from human brain; implications for Parkinson's disease. Science 293: 263-269, 2001
16. Moor DJ, West AB, Dawson VL, Dawson TM: Molecular pathophysiology of Parkinson's disease. Ann Rev Neurosci 28: 57-87, 2005
17. Yamamura Y, Sobue I, Ando K, Iida M, Yanagi T, et al: Paralysis agitans of early onset with marked diurnal fluctuation of symptoms. Neurology 23: 239-244, 1973
18. Ishikawa A, Tsuji S: Clinical analysis of 17 patients in 12 Japanese families with autosomal -recessive type juvenile parkinsonism. Neurology 47: 160-166, 1996
19. Mori H, Kondo T, Yokochi M, Matsumine H, Nakagawa-Hattori Y, et al: Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 51: 890-892, 1998
20. van de Warrenburg GPC, Lammens M, Lucking CB, Denefle P, Wesseling P, et al: Clinical and pathologic abnormalities in a a family with parkinsonism and parkin gene mutations. Neurology 56: 555-557, 2001
21. Farrer M, Chan P, Chen R, Tan L, Lincoln S, et al: Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 50: 293-300, 2001
22. Sasaki S, Shirata A, Yamane K, Iwata M: Parkin-positive autosomal recessive juvenile parkinsonism with alpha-synuclein-positive inclusions. Neurology 63: 678-682, 2004
23. Ohsawa Y, Kurokawa M, Sonoo H, Yamada S, Hemmi S, et al: Reduced amplitude of the sural nerve sensory action potential in PARK2 patients. Neurology 65: 459-462, 2005
24. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, et al : Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392: 605-608, 1998
25. Hoenicka J, Vidal L, Morales B, Ampuero I, Jimenez-Jimenez F, et al: Molecular findings in familial Parkinson disease in Spain. Arch Neurol 59: 966-970, 2002
26. Oliveira SA, Scott WK, Martin ER, Nance MA, Watts RL, et al: Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol 53: 624-629, 2003
27. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, et al: Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25: 302-305, 2000
28. Jiant H, Ren Y, Zhao J, Feng J: Parkin promotes human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum Molec Genet 13: 1745-1754, 2004
29. Moore DJ, Zhang L, Troncoso J, Lee MK, Hattori N, et al: Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum Molec Genet 14: 71-84, 2005
30. Lipton SA, Nakamura T, Yao D, Shi ZQ, Uehara T, et al: Comment on 'S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function'. Science 308; 1870b, 2005
31. Gasser T, Muller-Myhsok B, Wszolek ZK, Oehlmann R, Calne DB, et al: A susceptibirity locus for Parkinson's disease map to chromosome 2p13. Nat Genet 18: 262-265, 1998
32. Denson MA, Wszolek ZK, Pfeiffer RF, Wszolek EK, Paschall TM, et al: Familial Parkinsonism, dementia, and Lewy body disease: study of family G. Ann Neurol 42: 638-643, 1997
33. Waters C, Miller CA: Autosomal dominant Lewy body parkinsonism in a for-generation family. Ann Nerol 35: 59-64, 1994
34. Muenter MD, Forno LS, Hornykiewicz O, Kish SJ, Maraganor D, et al: Hereditary form of parkinsonism-dementia. Ann Neurol 43: 768-781, 1998
35. Gwinn-Hardy K, Mehta ND, Farrer M, Maraganore D, Muenter M, et al : Distinctive neuropathology revealed by alpha-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p. Acta Neurolath 99: 663-672, 2000
36. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, et al: Alpha-synuclein locus triplication causes Parkinson's disease. Science 302: 841, 2003
37. Farrer M, Kachergus J, Forno L, Lincoln S, Wang DS, et al: Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 55: 174-179, 2004
38. Nishioka K, Hayashi S, Farrer MJ, Singleton AB, Yoshino H, et al: Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann Neurol 59: 298-309, 2006
39. Fuchs J, Nilsson C, Kachergus J, Munz M, Larsson EM, et al: Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 68: 916-922, 2007
40. Ross OA, Braithwaite AT, Skipper LM, Kachergus J, Hulihan MM, et al: Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol 63: 743-750, 2008
41. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, et al: The ubiquitin pathoway in Parkinson's disease. Nature 395: 451-452, 1998
42. Albanese A, Valente EM, Romito LM, Bellaccho E, Elia AE, et al: The PINK1 phenotype can be indistinguishable from idiopathic Parkinson disease. Neurology 64: 1958-1960, 2005
43. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MMK, Harvey K, et al: Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304: 1158-1160, 2004
44. Hatano Y, Sato K, Elibol B, Yoshino H, Yamamura Y, et al: Novel PINK1: PARK6-linked autosomal ressecive early-onset parkinsonism in Asian population. Neurology 63: 1482-1485, 2004
45. Park J, Lee SB, Lee S, Kim Y, Song S, et al: Mitochondrial dysfunction in Drosophila PINKq mutations is complemented by parkin. Nature 441: 1157- 1161, 2006
46. Clark EI, Dodson MW, Jiang C, Cao JH, Huh JR, et al: Drosophila pinkl is required for mitochondrial function and interacts genetically with parkin. Nature 441: 1162-1166, 2006
47. Yang Y, Gehrke S, Imai Y, Huang Z, Ouyang Y, et al: Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pinkl is rescued by parkin. Proc Nat Acad Sci U S A 103: 10793-10798, 2006
48. Tang B, Xiong H, Sun P, Zhan Y, Wang D, et al: Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. Hum Molec Genet 15: 1816-1825, 2006
49. Van Duijn CM, Dekker MCJ, Bonifati V, Galjaard RJ, Houwing-Duistermaat JJ, et al: PARK7, novel- locus for autosomal recessive early-onset parkinsonism, on chromosome lp36. Am J Hum Genet 69: 629-634, 2001
50. Abou-sliman PM, Healy DG, Quinn N, Lees AJ, Wood NW: The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann Neurol 54: 283-286, 2003
51. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, et al: Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299: 256-259, 2003
52. Xu J, Zhong N, Wang H, Elias JE, Kim CY, et al: The Parkinson's disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis. Hum Mol Genet 14: 1231-1241, 2005
53. Hasegawa K, Funayama M, Matsuura N, Furusawa H, Sakai F, et al: Analysis of a-synuclein, parkin, tau, and UCH-L1 in a Japanese family with autosomal dominant parkinsonism. Eur Neurol 46: 20-24, 2001
54. Funayama M, Hasegawa K, Kowa H, Satio M, Tsuji S, et al: A new locus for Parkinson's disease (PARK 8) maps to chromosome 12pll.2-ql3.1.An Neurol 51: 296-301, 2002
55. Zimprich A, Muller-Myhsok B, Farrer M, Leitner P, Sharma M, et al: The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet 74: 11-19, 2004
56. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, et al: Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44: 598-600, 2004
57. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, et al: Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44: 601-607, 2004
58. Funayama M, Hasegawa K, Ohta E, Kawashima N, Komiyama M, et al:An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family Ann Neurol 57: 918-921, 2005
59. Paisan-Ruiz C, Saenz A, de Mutain AL, Marti I, Martinez GA, et al: Familial Parkinson's disease: clinical and genetic analysis of for Basque families. Ann Neurol 57: 365-372, 2005
60. Hernandes DG, Paisan-Ruiz C, Mclnerny-Leo A, et al: Clinical and positron emission tomography of Parkinson's disease caused by LRRK2. Ann Neurol 57: 453-456, 2005
61. Khan NL, Jain S, Lznch JM, Pavese N, Abou-Sleiman P, et al: Mutation in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 128: 2786-2796, 2005
62. Adams JR, van Netten H, Schulzer M, Mak E, Mckenzie J, et al: PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 128: 2777-2785, 2005
63. Hasegawa K, Stoessl AJ, Yokoyama T, Kowa H, Wszolek ZK, et al: Familial parkinsonism: Study of original Sagamihara PARK8 (I2020T) kindred wit variable clinicopathologic outcomes. Parkinsonism Relat Disord 2008 Sep 18 (Epub ahead of print)
64. Wszolek ZK, Pfeiffer RF, Tsuboi Y, Uitti RJ, McComb RD, et al: Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 62: 1619-1622, 2004
65. Wszolek ZK, Vieregge P, Uitti RJ, Gasser T, Yasuhara O, et al: German-Canadian family (family A) with parkinsonism, amyotrophy, and dementia- longitudinal observations. Parkinsonism Relat Disord 3: 125-139, 1997
66. Ross OA, Toft M, Whittle AJ, Johnson JL, Papapetropoulos S, et al: Lrrk2 and Lewy body disease. Ann Neurol 59: 288-292, 2006
67. Nichols WC, Pankratz N, Hernandez D, Paisan-Ruiz C, Jain S, et al: Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 365: 410-412, 2005
68. Di Fonzo A, Rohe CF, Ferreira J, Chien HF, Vacca L, et al: A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 365: 412-415, 2005
69. Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, et al: A common LRRK2 mutation in idiopathic Parkinson's disease.Lancet 365: 415-416, 2005
70. Mata IF, Ross OA, Kachergus J, Huerta C, Ribacoba R, et al: LRRK2 mutations are a common cause of Parkinson's disease in Spain. Eur J Neurol 13: 391- 394, 2006
71. Di Fonzo A, Wu-Chu YH, Lu CS, van Doeselaar M, Simons EJ, Rohe CF, et al: A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 7: 133-138, 2006
72. Saunders-Pullman R, Lipton RB, Senthil G, Katz M, Costan-Toth C, et al: Increased frequency of the LRRK2 G2019S mutation in an elderly Ashkenazi Jewish population is not associated with dementia. Neurosci Lett 402: 92-96, 2006
73. Marongiu R, Ghezzi D, Ialongo T, Soleti F, Elia A, et al: Frequency and phenotypes of LRRK2 G2019S mutation in Italian patients with Parkinson's disease. Mov Disord 21: 1232-1235, 2006
74. Williqmw-Gray CH, Goris A, Foltynie T, Brown J, Maranian M, et al: Prevalence of the LRRKw G2019S mutation in a UK community based idiopathic Parkinson's disease cohort. J Neurol Neurosurg Psychiatry 77: 665-667, 2006
75. Gaig C, Ezquerra M, Marti MJ, Munoz E, Valldeoriola F, et al: LRRK2 mutations in Spanich patients with Parkinson disease:frequency, clinical features, and incomplete penetrance. Arh Neurol 63: 377-382, 2006
76. Infante J, Rodriguez E, Combarros O, Mateo I, Fontalba A, et al: LRRK2 G2019S is a common mutation in Spanich patients with late-onset Parkinson's disease. Neurosci Lett 395: 224-226, 2006
77. Hernandez D, Ruiz CP, Crawley A, Roneil M, Werner J, et al: The dardarin G2019S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases. Neurosci Lett 389: 137-139, 2005
78. Tomiyama H, Li Y, Funayama M, Hasegawa K, Yoshino H, et al: Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. Mov Disord 21: 1102-1108, 2006
79. Bosgraaf L, Van Haastert PJ: Roc, a Ras/GTPase domain in complex proteins. Biochim Biophys Acta 1643: 5-10, 2003
80. Najim Al-Di AS, Mubaidin A, Dasouki M, Hiari M: Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia:Kufor-Rakeb syndrome. Acta Neurol Scand 89: 347-352, 1994
81. Hamishire DJ, Roberts E, Crow Y, Bond J, Mudaidin A, et al: Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to lp36. J Med Genet 38: 680-682, 2001
82. Williams DR, Hadeed A, Najim al-Din A, Wreikat A-L, Lee AJ: Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Mov Disord 20: 1264-1471, 2005
83. Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, et al: Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5P-type ATP ase. Nat Genet 38: 1184-1190, 2006
84. Lin CH, Tan EK, Chen ML, Tan LC, Lim HQ, et al: Novel ATP13A2 variant associated with Parkinson disease in Taiwan and Singapore. Neurology 71: 1727-1732, 2008
85. Hicks AA, Petursson H, Jonsson T, Stefansson H, Johannsdottir HS, et al: A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann Neurol 52: 549-555, 2002
86. Pankratz NM, Nichols WC, Uniacke SK, Halter C, Murrell J, et al: Genome-wide likage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Hum Molec Genet 12: 2599-2608, 2003
87. Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, et al: the Parkinson study group: Genome screen identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am J Hum Genet 71: 124-135, 2002
88. Strauss KM, Martins LM, Plun-Favreau H, Marx FP, Kautzmann S, et al: Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Molec Genet 14: 2099-2111, 2005
89. Ozerlius LJ, Hewett JW, Page CE, Bressman SB, Kramer PL, et al: The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet 17: 40-48, 1997
90. Risch NJ, Bressman SB, Senthil G, Ozelius LJ: Intragenic Cis and Trans modification of genetic susceptibility in DYT1 torsion dystonia. Am J Hum Genet 80: 1188-1193, 2007
91. Kustedjo K, Bracey MH, Cravatt BF: Torsin A and its torsion dystonia-associated mutant forms are lumenal glycoproteins that exhibit distinct subcellular localizations. J Biol Chem 275: 27933-27939, 2000
92. + protein torsinA interacts with a conserved domain present in LAP1 and a novel ER protein. J Cell Biol 168: 855- 862, 2005
93. Hewett JW, Tannous B, Niland BP, Nerv FC, Zeng J, et al: Mutant torsinA interferes with protein processing through the secretory pathway in DYT1 dystonia cells. Proc Natl Acad Sci U S A 104: 7271-7276, 2007
94. Goodchild RE, Kim CE, Dauer WT: Loss of the dystonia-associated protein torsinA selectively disrupts the neuronal nuclear envelope. Neuron 48: 923-932, 2005
95. Kustedjo K, Bracey MH, Cravatt BF: Torsin A and its torsion dystonia-associated mutant forms are lumenal glycoproteins that exhibit distinct subcellular localizations. J Biol Chem 275: 27933-27939, 2000
96. McNaught KP, Kapustin A, Jackson T, Jengelley TA, JnoBaptiste R, et al: Brainstem pathology in DYT1 primary torsin dystonia. Ann Neurol 56: 540- 547, 2004
97. Makino S, Kaji R, Ando S, Tomizawa M, Yasuno K, et al: Reduced neuron-specific expression of the TAF1 gene is associated with X-linked dystonia-parkinsonism. Am J Hum Genet 80: 393-406, 2007
98. Lee LV, Maranon E, Demisip C, Peralta O, Borres-I, Casiano R, et al: The natural history of sex-linked recessive dystonia parkinsonism of Panay, Philippines (XDP). Parkinsonism Relat Disord 9: 29- 38, 2002
99. Parker H: Hereditary whispering dysophoia. J Neurol Neurosurg Psychiatry 48: 218-224, 1985
100. Segawa M, Hosaka A, Miyagawa F, Nomura Y, Imai H: Hereditary progressive dystonia with marked diurnal fluctuation. Adv Neurol 14: 215-233, 1976
101. Ichinose H, Ohye T, Takahashi E, Seki N, Hori T, et al: Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet 8: 236-242, 1994
102. Almasy L, Bressman SB, Raymond D, Kramer PL, Greene PE, et al: Idiopathic torsion dystonia linked to chromosome 8 in two Mennonite families. Ann Neurol 42: 670-673, 1997
103. Klein C, Ozelius LJ, Hagenah J Breakefield XO, Risch NJ, et al: Search for a founder mutation in idiopathic focal dystonia from Northern Germany. Am J Hum Genet 63: 1777-1782, 1998
104. Rainier S, Thomas D, Tokarz D, Ming L, Bui M, et al: Myofibrillogenesis regulator 1 gene mutations cause paroxysmal dystonic choreoathetosis. Arch Neurol 61: 1025-1029, 2004
105. Lee H-Y, Xu Y, Huang Y, Ahn AH, Auburger GW, et al: The gene for paroxysmal non-kinesigenic dyskinesia encodes an enzyme in a stress response pathway. Hum Mol Genet 13: 3161-3170, 2004
106. Auburger G, Ratzlaff T, Lunkes A, Nelles HW, Leube B, et al: A gene for autosomal dominant paroxysmal choreoathetosis/spasticity (CSE) maps to the vicinity of a potassium channel gene cluster on chromosome lp, probably within 2 cM between D1S443 and D1S197. Genomics 31: 90-94, 1996
107. Tomita H, Nagamitsu S, Wakui K, Fukushima Y, Yamada K, et al: Paroxysmal kinesigenic choreoathetosis locus maps to chromosome 16pll.2-ql2.1. Am J Hum Genet 65: 1688-1697, 1999
108. Zimprich A, Grabowski M, Asmus F, Naumann M, Berg D, et al: Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet 29: 66-69, 2001
109. Espa CT, Waite A, Locke M, Benson MA, Kraus M, et al: SGCE missense mutations that cause myoclonus-dystonia syndrome impair ε-sarcoblycan trafficking to the plasmamembrane: modulation by ubiquitination and torsinA. Hum Mol Genet 16: 327- 342, 2007
110. de Carvalho Aguiar P, Sweadner KJ, Penniston JT, Zaremba J, Liu L, et al: Mutations in the Na( + )/ K( + )-ATPase alpha-3 gene ATP1A3 are associated with rapid-onset dystonia parkinsonism. Neuron 43: 169-175, 2004
111. Valente EM, Bentivoglio AR, Cassetta E, Dixon PH, Davis MB, et al: DYT13, a novel primary torsion dystonia locus, maps to chromosome lp36.13-36.32 in an Italian family with cranial-cervical or upper limb onset. Ann Neurol 49: 362-366, 2001
112. Wider C, Melquist S, Häuf M, Solida A, Cobb S, et al: Study of a Swiss dopa-responsive dystonia family with a deletion in GCH1: redefining DYT14 as DYT5. Neurology 70: 1377-1383, 2008
113. Grimes DA, Han F, Lang AE, St. George-Hyslop P, Racacho L, et al : A novel locus for inherited myoclonus-dystonia on 18pll. Neurology 59: 1183- 1186, 2002
114. Camargos S, Scholz S, Simon-Sanchez J, Paisan-Ruiz C, Lewis P, et al: DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurol 7: 207-215, 2008
115. Chouery E, Kfoury J, Delague V, Jalkh N, Bejjani P, et al : A novel locus for autosomal recessive primary torsion dystonia (DYT17) maps to 20pll.22-ql3.12. Neurogenetics 9: 287-293, 2008
116. Margari L, Perniola T, Illiceto G, Ferrannini E, De Iaco MG, et al: Familial paroxysmal exercise- induced dyskinesia and benign epilepsy: a clinical and neurophysiological study of an uncommon disorder. Neurol Sci 21: 165-172, 2000
117. Munchau A, Valente EM, Shahidi GA, Eunson LH, Hannna MG, et al: A new family with parozysmal exercise induced dystonia and migraine: a clinical and genetic study. J Neurol Neurosurg Psychiat 68: 609-614, 2000
118. Weber YG, Storch A, Wuttke TV, Brockmann K, Kempfle J, et al: GLUTI mutations are a cause of parozysmal exertion-induced dyskinesia and induce hemolytic anenmia by a cation leak. J Clin Invest 118: 2157-2168, 2008
119. Valente EM, Spacey SD, Wali GM, Bhatia KP, Dixon PH, et al: A second paroxysmal kinesigenic choreoathetosis locus (EKD2) mapping on 16ql3-q22.1 indicates a family of genes which give rise to paroxysmal disorders on human chromosome 16. Brain 123: 2040-2045, 2000
120. Spacey SD, Adams PJ, Lam PCP, Materek LA, Stoessl AJ, et al: Genetic heterogeneity in paroxysmal nonkinesigenic dyskinesia. Neurology 66: 1588- 1590, 2006